Evidence map›Paper›PMID 31021005›Full record

ArticleAmerican journal of hematology2019

Weekly carfilzomib, lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: A phase 1b study.

Noa Biran, David Siegel, Jesus G Berdeja, Noopur Raje, Robert Frank Cornell, Melissa Alsina, Tibor Kovacsovics, Belle Fang, Amy S Kimball, Ola Landgren

2 registry-linked trialsOpen access · hybridAbstract readClinical Trial, Phase IMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of hematology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02335983 phase1completednot on this map

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma

TypeinterventionalSponsorAmgenRan2015 to 2019Enrolled107ConditionsMultiple MyelomaArmsCarfilzomib, Lenalidomide, Dexamethasone
NCT05199311 phase1 / phase2suspendednot on this mapstarted 2022, after this paper: background citation

A Phase I/II Study of Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Patients With Newly Diagnosed Transplant Eligible Multiple Myeloma

TypeinterventionalSponsorHackensack Meridian HealthRan2022 to 2027Enrolled66ConditionsMultiple MyelomaArmsCarfilzomib, Iberdomide, Oral Dexamethasone
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 15 citations in OpenAlex.

  1. Trial
  2. Improving the Dosing Schedules of Targeted Anticancer Agents.Pharmaceuticals (Basel, Switzerland) · 2025
    Review
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 8 institutions in 1 country.

Noa BiranMyeloma Division, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey.ORCID 0000-0003-0693-4202
David SiegelMyeloma Division, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey.
Jesus G BerdejaDepartment of Medicine, Sarah Cannon Research Institute, Nashville, Tennessee.
Noopur RajeDepartment of Hematology and Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts.
Robert Frank CornellDivision of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, Tennessee.
Melissa AlsinaDepartment of Blood and Marrow Transplantation, Moffit Cancer Center, Tampa, Florida.
Tibor KovacsovicsDivision of Hematology and Hematologic Malignancies, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, Utah.
Belle FangGlobal Biostatistical Science, Amgen Inc., Thousand Oaks, California.
Amy S KimballGlobal Development, Amgen Inc., Thousand Oaks, California.
Ola LandgrenDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York City, New York.
Amgen (United States) · USHackensack University Medical Center · USMassachusetts General Hospital · USMemorial Sloan Kettering Cancer Center · USMoffitt Cancer Center · USSarah Cannon · USUniversity of Utah · USVanderbilt University Medical Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Amgen, Inc.NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Twice-weekly carfilzomib (27 mg/m

Indexed as

AdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsDexamethasoneFemaleHumansLenalidomideMaleMiddle AgedMultiple MyelomaOligopeptidesRecurrencecarfilzomibDexamethasoneLenalidomideOligopeptides

Identifiers

PMID31021005
PMCPMC6593978
OpenAlexW2941501187

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.